Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALANIS: Belantamab Mafodotin + CyBorD in Newly Diagnosed AL Amyloidosis
NCT07224672Phase 2Recruiting
- Sponsor
- GSK
- Start
- Jun 2026
- Primary completion
- Jan 2033
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
A Phase 2 trial of belantamab mafodotin in amyloid light chain amyloidosis, sponsored by GSK. Started Jun 2026; status: recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT07224672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07224672.